SAGE Therapeutics (NASDAQ:SAGE) was downgraded by BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Tuesday.

A number of other analysts have also commented on the company. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of SAGE Therapeutics in a research note on Wednesday, January 10th. Royal Bank of Canada raised their price target on SAGE Therapeutics from $137.00 to $280.00 and gave the stock a “sell” rating in a research note on Thursday, December 7th. They noted that the move was a valuation call. Chardan Capital raised SAGE Therapeutics from a “neutral” rating to a “buy” rating and raised their price target for the stock from $60.00 to $140.00 in a research note on Friday, November 10th. Cowen reaffirmed a “buy” rating on shares of SAGE Therapeutics in a research note on Monday, December 11th. Finally, Leerink Swann raised their price target on SAGE Therapeutics from $123.00 to $246.00 in a research note on Thursday, December 7th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and twelve have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $171.21.

Shares of SAGE Therapeutics (SAGE) opened at $159.34 on Tuesday. SAGE Therapeutics has a 52 week low of $47.06 and a 52 week high of $195.97. The company has a market capitalization of $6,540.00, a price-to-earnings ratio of -23.19 and a beta of 2.97.

In other SAGE Therapeutics news, CEO Jeffrey M. Jonas sold 210,247 shares of the firm’s stock in a transaction on Thursday, December 21st. The stock was sold at an average price of $157.45, for a total transaction of $33,103,390.15. Following the completion of the transaction, the chief executive officer now owns 211,473 shares of the company’s stock, valued at $33,296,423.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Albert Robichaud sold 60,000 shares of the firm’s stock in a transaction on Thursday, December 14th. The shares were sold at an average price of $159.43, for a total value of $9,565,800.00. Following the transaction, the insider now directly owns 152,759 shares of the company’s stock, valued at approximately $24,354,367.37. The disclosure for this sale can be found here. Insiders have sold 314,247 shares of company stock valued at $50,465,110 in the last three months. Insiders own 6.10% of the company’s stock.

Institutional investors have recently made changes to their positions in the business. Ameriprise Financial Inc. grew its position in SAGE Therapeutics by 0.9% in the 2nd quarter. Ameriprise Financial Inc. now owns 59,336 shares of the biopharmaceutical company’s stock valued at $4,723,000 after acquiring an additional 552 shares during the last quarter. New York State Common Retirement Fund lifted its holdings in shares of SAGE Therapeutics by 9.1% in the 2nd quarter. New York State Common Retirement Fund now owns 41,782 shares of the biopharmaceutical company’s stock valued at $3,328,000 after purchasing an additional 3,499 shares during the last quarter. Northern Trust Corp lifted its holdings in shares of SAGE Therapeutics by 17.9% in the 2nd quarter. Northern Trust Corp now owns 411,444 shares of the biopharmaceutical company’s stock valued at $32,767,000 after purchasing an additional 62,474 shares during the last quarter. Voya Investment Management LLC lifted its holdings in shares of SAGE Therapeutics by 37.5% in the 2nd quarter. Voya Investment Management LLC now owns 16,025 shares of the biopharmaceutical company’s stock valued at $1,276,000 after purchasing an additional 4,371 shares during the last quarter. Finally, Stifel Financial Corp purchased a new stake in shares of SAGE Therapeutics in the 2nd quarter valued at about $401,000. 95.47% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This report was originally posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://theolympiareport.com/2018/02/13/bidaskclub-lowers-sage-therapeutics-sage-to-sell.html.

SAGE Therapeutics Company Profile

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Analyst Recommendations for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.